Time to Buy: VIVUS?

In this entry, David and Austin focus on VIVUS, which saw shares clobbered in July. Is it time to invest in this cutting-edge company on the cheap, or is the poor month a sign of further troubles ahead? Watch and find out.

When it comes to do-or-die busineses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, though, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

The article Time to Buy: VIVUS? originally appeared on Fool.com.

Austin Smith, Dave Williamson, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.